DAFTAR PUSTAKA

Abdullah, N., 2009. Analisis polimorfisme gen Vascular Endothelial Growth Factor (VEGF) pada endometriosis. *Maj Obstet Ginekol Indones*;33(2):108-117.

Abougalambou, S. S. I., Hassali, M.A., Sulaiman, S.A.S., Abougalambou, A.S., 2011. Prevalence of vascular complications among type 2 diabetes mellitus outpatients at teaching hospital in Malaysia', *J Diabetes Metab*;2(115):1–4.

Al-Ani, F.S., Al-Nimer, M.S., Ali, F.S., 2011. Dyslipidemia as a contributory factor in ethiopathogenesis of diabetic neuropathy. *Indian J Endocrinol Metab*;15(2):110-114

Alber, H.F., Dulak, J., Frick, M., Dichtl, W., Scwarzacher, P., Pachinger, O., Weidinger F., 2002. Atorvastatin decreases Vascular Endothelial Growth Factor in Patients with Coronary Artery Disease. *J Am Coll Cardiol*;39(12):1951-1955.

Alber, H.F., Frick, M., Dulak, J., Dorler, J., Zwick R.H., Dichtl W., Pachinger, O., Weidinger F., 2005. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. *Heart*;91:365-366.

Alexander, L. K., Lopes, B., Ricchetti-Masterson, K., Yeatts, K.B., 2013. Cross-sectional studies. UNC Gillings School of Global Public Health. https://sph.unc.edu/files/2015/07/nciph_ERIC8.pdf

American Academy of Neurology. 2002. Statin drugs may increase risk of peripheral neuropathy. https://www.aan.com/PressRoom/Home/PressRelease/82

American Diabetes Association. 2012. Excecutive Summary: Standards of Medical Care in Diabetes – 2018 Abridge for Primary Care Providers. *Clin Diabetes*; 36(1): 14-37

Amoli, M.M., Hasani-Ranjbar, S., Roohipour, N., Sayahpour, F. A., Amiri, P., Zahedi, P., Mehrab-Mohseni, M., Heshmat, R., Larijani, B.,

Tavakkoly-Bazzaz, J., 2011. VEGF gene polymorphism association with diabetic foot ulcer. *Diabetes Res Clin Pract*;93:215-219.

Asad, A., Hameed, M.A., Khan, U.A., Butt, M.R.A., Ahmed, N., and Nadeem, A., 2009. Comparison of nerve conduction studies with diabetic neuropathy symptom score and diabetic neuropathy examination score in type-2 diabetics for detection of sensorimotor polyneuropathy. *JPMA*;59:594 – 598

Bae, S. J., Kim, J.W., Kang, H., Hwang, S.G., Oh, D., Kim, N.K., 2008. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C> T) gene and colon cancer in Korea. *Anticancer Res*; 28(2B):1271–1276.

Bhutani, J., and Bhutani, S. 2014. Worldwide burden of diabetes. *Indian J Endocrinol Metab*; 18(6): 868–870.

Boulton, A.J.M., 2010. The diabetic foot. *Medicine*;38(12):644 – 648

Boulton, A.J.M., Vinik, A.I., Arezzo, J.C., Brill, V., Feldman, E.L., Freeman, R., Malik, R.A., Maser, R.E., Sosenko, J.M., and Ziegler, D., 2005. Diabetic neuropathies: A statement by the American Diabetes Association. *Diabetes Care*;28(4):956-962.

Brownlee, M., 2005. Banting Lecture 2004: The pathobiology of diabetic complications, a unifiying mechanism. *Diabetes*;54:1615-1625.

Buschbacher R. M., *Manual of Nerve Conduction Studies*, Demos Medical Publishing, New York, pp 240-243.

Buschbacher R. M., Prahlow, N.D., 2006. *Manual of Nerve Conduction Studies*, 2nd Ed. Demos Medical Publishing, New York, pp 6-248.

Cade, W.T., 2008. Diabetes related microvascular and macrovascular diseases in the physical therapy setting. *Phys Ther*;88(11):1322-1335.

Carrington, A.L., Shaw, J.E., Van Schie, C.H.M., Abbot, C.A., Vileikyte, L.A., Boulton, A.J.M., 2002. Can motor nerve conduction velocity predict foot problems in diabetic subject over a 6-year outcome period? *Diabetes Care*;25:2010-2015.

Chung, T., Prasad, K., Lloyd, T.E., 2014. Peripheral Neuropathy: Clinical and electrophysiological consideration. *Neuroimag Clin N Am*;24:49-65.

Deguchi, T., Hashiguchi, T., Horinouchi, S., Uto, T., Kimura, K., Makisumi, K., Arimura, K., 2009. Serum VEGF increases in diabetic polyneuropathy, particularly in the neurological active symptomatic stage. *Diabet Med*;26:247-252.

De Jager, J., Kooy, A., Lehert, P., Wulffelé, M.G., Van der Kolk, J., Bets, D., Verburg, J., Donker, A.J. and Stehouwer, C.D., 2010. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *BMJ*;*340*:c2181.

Doupis, J., Lyons, T.E., Wu, S., Gnardellis, C., Dinh, T., Veves, A., 2009. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy, *J Clin Endocrinol Metab*; 94(6): 2157–2163.

Dyck P.J., Giannini, C., 1996. Pathologic alterations in the diabetic neuropathies in humans. A review. *J Neuropathol Exp Neurol*;55(12):1181-1193

Dyck, P.J., Albers J.W., Andersen, H., Arezzo, J.C., Biessels, G., Bril, V., et al., 2011. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. *Diabetes Metab Res Rev*;27:620-628.

Duh, E., and Aiello, L. P. 1999. Vascular Endothelial Growth Factor and Diabetes the Agonist versus antagonist paradox. *Diabetes*;48:1899-1906.

Dupont, W.D., and Plummer, W.D. 1990. Power and Sample Size Calculation: A Review and Computer Program. *Control Clin Trial*;11:116-128.

Edwards, J.L., Vincent A., Cheng, T., Feldman, E.L., 2008. Diabetic Neuropathy: Mechanism to Management. *Pharmacol Ther*;120(1):1-34.

Eichman, A., and Simons, M. 2012. VEGF signaling inside vascular endothelial cells and beyond. *Cur Opin Cell Biol*;24:188-193.

Elias I., Franckhauser, S., Bosch, F., 2013. Ner insights into adipose tissue VEGF-A actions in the control of obesity and insulin resistance. *Adipocyte*;2(2):109-112.

England, J.D., Gronseth, G.S., Franklin, G., Milled, R.G., Asbury, A.K., Carter, G.T., Cohen, J.A., Fisher, M.A., Howard, J.F., Kinsella, L.J., Latov, N., Lewis, R.A., Low, P.A., Sumner, A.J., 2005. Distal symmetric polyneuropathy: A definition for clinical research. *Neurology*;64:199-207.

Ferrara, N., 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. *Am J Physiol Cell Physiol;*280:C1358-1366.

Ferrara, N., and Davis-Smith, T. 1997. The biology of vascular endothelial growth factor. *Endocr Rev*; 18:4-25.

Fithrie, A., Hakim, M., Octaviana, F., Yanuar, A., 2011. Nilai Normal gelombang F di Ekstremitas Atas dan Bawah. Departemen Neurologi Fakultas Kedokteran Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo. Jakarta.

Franssen, H., Van Den Berg, P.Y.K., 2006. Nerve conduction studies in polyneuropathy: practical physiology and patterns of abnormality. *Acta Neurol Belg*;106:73-81.

Fuglsang-Frederiksen, and A., Pugdahl, K. 2011. Current status on electrodiagnostic standards and guidelines in neuromuscular disorders. *Clin Neurophysiol*;122:440-455.

Girach, A., Manner, D., Porta, M., 2006. Diabetic microvascular complications: can patients at risk be identified? A review. *Int J Clin Pract*;60(11):1471-1483.

Ghisleni, M.M., Biolchi, V., Jordon, B.C., Rempel, C., Genro, J.P., and Pozzobon, A., 2015. Association study of C936T polymorphism of the VEGF gene and the C242T polymorphism of the p22phox gene with diabetes mellitus type 2 and distal diabetic polyneuropathy. *Mol Med Rep*;12(3):4626-4633.

Giacco, F., Brownlee, M., 2010. Oxidative stress and Diabetic Complications. *Circ Res*;107:1058-1070.

Grote, C.W. and Wright, D.E., 2016. A role for insulin in diabetic neuropathy. *Front Neurosci;*10:581.

Guo, Y., Palmer J. L., Brown, X.S., Fu, J.B., 2015. Sural and Radial Sensory Responses in Patients with Sensory Polyneuropathy. *Clin Med Rev Case Rep*;2(3):1-7.

Habibur, RM., Kumar, JM., Suk, K., 2015. Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets. *Curr Pharm Des*;22:1-20.

Han, L., Zhang, L., Xing, W., Zhuo, R., Lin, X., Hao, Y., Wu, Q. and Zhao, J., 2014. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. *Journal of diabetes research*, *2014*.

Happich, M., John, J., Stamenitis, S., Clouth, J., Polnau, D., 2008. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002 – Results from the diabetic microvascular complications (DIMICO) study. *Diab Res Clin Pract*; 81:223-230.

Harati, Y., 2007. Diabetic Neuropathies: Unanswered Questions. *Neurol Clin*;25:303-317.

Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., De Bruijn, E. A., 2004. Vascular Endothelial Growth Factor and Angiogenesis. *Pharmacol Rev*;56(4):549-580.

Hoseini, A., Abdollahi, M., 2013. Diabetic neuropathy and oxidative stress: therapeutic perspectives. *Oxid Med Cell Longev*;2013:1-15.

Hunter, D.J., 2005. Gene – Environment interactions in human diseases. *Hum Nat*;6:287-298

Hunter, T., 2011. Diabetic peripheral neuropathy, *Drug Topics:*40-51.

Javed, S., Petropoulos, I.N., Alam, U., Malik, R.A., 2015. Treatment of painful diabetic neuropathy. *Ther Adv Chronic Dis*;6(1):15-28.

Kanda, T., 2013. Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. *J Neurol Neurosurg Psychiatry*;84:208-212.

Kasiulevicus, V., Sapoka, V., Filipaviviute, R., 2006. Sample size calculation in epidemiological studies. *Gerontologija*;7(4):225-231.

Kaur, J., 2013. An overview of Diabetic Neuropathy. *Annu Res Res Biol*;3(4):994-1012.

Khanolkar, M.P., Bain, S.C., Stephens, J.W., 2008. The diabetic foot. *Q J Med*;101:685 – 695.

Khawaja, N., Abu-Shennar, J., Saleh, M, Dahbour, S.S., Khader, Y.S., Ajlouni, K.M., 2018. The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan. *Diabetol Metab Syndr*;10(8):1-10

Kiernan, M.C., 2011. Nerve conduction studies. *Aust Fam Phys*;40(9):693-697

Kipnes, M. S., Ando, D. G., & Cornblath, D. R., 2006. Single Treatment, Phase 1b Placebo Controlled Trial of a Zinc Finger Growth Factor (ZFP) Activator (SB-509) of a Vascular Endothelial Growth Factor (VEGF) in Subjects with Diabetic Neuropathy (DN)[Abstract 1989-PO]. In *66th annual meeting of the American Diabetes Association*.

Kim, H.W., Ko, G.J., Kang, Y.S., Lee, M. H., Song, H. K., Kim, H.K., and Cha, D.R. 2009. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. *Nephrology*;14:681-688.

Ko, S.H., Cha, B.Y., 2012. Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus in Korea. *Diabetes Metab J*;36:6-12.

Kohara, N., Kimura, J., Kaji, R., Goto, Y., Ishii, J., Takiguchi, M., Nakai, M., 2000. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicenter analysis in healthy subjects and patients with diabetic polyneuropathy. *Diabetologia*;43:915-921.

Krippl P., Langsenlehner, U., Renner, W., Yazdani-Biuki, B., Wolf, G., Wascher, T.C., et al. A Common 936 C/T Gene Polymorphism of Vascular Endothelial Growth Factor is Associated with Decreased Breast Cancer Risk. *Int J Cancer*;106:468-471.

LaMorte, W.W. 2016. Confounding and Effect Measure Modification. MPH Online Learning Module, Boston University School of Public Health. Available at http://sphweb.bumc.bu.edu/otlt/MPH-Modules/BS/BS704-EP713_Confounding-EM/BS704-EP713_Confounding-EM3.html

Leinninger, G.M., Vincent, A. M., Feldman, E. L., 2004. The role of growth factors in diabetic peripheral neuropathy. *J Peripher Nerv Sys*;9:26-53.

Lin, L., Cao, K., Chen, W., Pan, X., and Zhao, H., 2013. Four common Vascular Endothelial Growth Factor polymorphysm (-2578C>A, -460C>T, +936C>T, and +405G>C) in susceptibility to lung cancer: A Meta Analysis. *PLOS ONE*;8(10):1-11.

Llewelyn, J.G., 2003. The diabetic neuropathies: types, diagnosis, and management. *J Neurol Neurosurg Psychiatry*;74(Suppl II):ii15-ii19.

Malik, R.A., 2014. Pathology of human diabetic neuropathy. In. Zochodne, D.W., Malik, R.A. (Eds), Handbook of Clinical Neurology 3rd series, Elsevier USA pp. 249-259

Mallik, A. and Weir, A.I., 2005. Nerve conduction studies: essentials and pitfalls in practice. *Journal of Neurology, Neurosurgery & Psychiatry*;*76*(suppl 2):pp.ii23-ii31.

Mardastuti, Y., Asmedi A., 2013. Uji Reliabilitas dan Validitas Diabetic Neuropathy Symptom (DNS-INA) dan Diabetic Neuropathy Examination (DNE-INA) sebagai Skor Diagnostik Neuropati Diabetik. Universitas Gadjah Mada (Thesis).

Marshall, S. M. and Flyvbjerg, A. (2006) 'Prevention and early detection of vascular complications of diabetes', *BMJ*, 333(7566), pp. 475–480.

McNeil, C.J., Butler, J.E., Taylor, J.L., Gandevia, S.C., 2013. Testing the excitability of human motoneurons. *Front Hum Neurosci*;7:1-9.

Meerwald R., Links, T., Zeebregts, C., Tio, R., Hillebrands, J.L., Smit, A., 2008. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. *Cardiovasc Diabetol*;7:29

Meijer, J.G., van Sonderen, E., Blaauwwiekel, E.E., Smit, A.J., Groothofe, J.W., Eisma, W.H., and Links, T.P., 2000. Diabetic Neuropathy Examination. A hierarchical scoring system to diagnose distal polyneuropathy in diabetes. *Diabetes Care*;23:750-753.

Meijer, J.G., Bosma, E., Lefrandt, J.D., Links, T.P., Smit, A.J., Stewart, R.E., van der Hoven, J.H., and Hoogenberg, K., 2003. Clinical diagnosis of diabetic polyneuropathy with the Diabetic Neuropathy Symptom and Diabetic Neuropathy Examination scores. *Diabetes Care*;26:697-701.

Misulis, K.E., and Head, T.C. 2003. Basic Principles of Nerve Conduction Study and Electromyography. In. Essentials of Clinical Neurophysiology, 3rd Ed. Elsevier Science, USA, pp.129-160.

Moscu, B., and Pereanu, M. 2011. Pathophysiological features in diabetic neuropathy. *AMT*;2(1):268-271.

Motawi, T. K. *et al.* (2014) 'Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy', *Cell biochemistry and function*, 32(2), pp. 155–163.

Mythili, A., Kumar, D., Subrahmanyam, K.A.V., Venkateswarlu, K., Butchi, R. G., 2010. A comparative study of examination scores and

quantitative sensory testing in diagnosis of diabetic neuropathy. *Int J Diabetes Dev Ctries*;30(1):43-48

Novak P., Pimentel, D.A., Sundar, B., Moonis, M., Qin, L., Novak, V. 2015. Association of statins with sensory and autonomic ganglionopathy. *Front Aging Neurosci*;7:191.

Nowacka, M. M., Obuchowicz, E., 2012. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action, *Neuropeptides*;46(1):1–10.

Nukada, H., 2014. Ischemia and diabetic neuropathy. In: Zochodne, D.W., & Malik, R.A. Eds. *Handbook of Clinical Neurology: Diabetes and the Nervous System*, Elsevier, pp.469-487

Ozturk, B.T., Bozkurt, B., Kerimoglu, H., Okka, M., Kamis, U., and Gunduz, K., 2009. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. *Mol Vis*;15:1906-1914.

Perez-Maltos, M.C., Morales-Alvarez, M.C., Mendivil, C.O., 2017. Lipids: a suitable therapeutic target in diabetic neuropathy? *J Diabetes Res*; Article ID 6943851, 9 pages

Perkins, B., Bril, V., 2014. Electrophysiologic testing in diabetic neuropathy. *Handbook of Clinical Neurology,* Elsevier.

Poduslo, J.F., Curran, G.L., 1992. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. *Proc. Natl. Acad. Sci. USA*;89:2218-2222.

Poernomo, H., Basuki, M., Widjaja, D., 2003. *Petunjuk Praktis Elektrodiagnostik*. Bagian Ilmu Penyakit Saraf Fakultas Kedokteran Universitas Airlangga, Airlangga University Press, Surabaya pp.112-157; 227.

Pop-Busui, R., Sima, A., Stevens, M., 2006. Diabetic neuropathy and oxidative stress. *Diabetes Metab Res Rev*;22:257-273.

Prabodha, I.B.I., Sirisena, N.D., Dissanayake, V.G.W., 2018. Susceptible and prognostic genetic factors associated with diabetic peripheral neuropathy: a comprehensive literature review. *Int J Endocrinol*; vol. 2018, Article ID 8641942, 9 pages

Renner, W., Kotschan S., Hoffman, C., Obermayer-Pietsch, and Pilger, E., 2000. A common 936 C/T mutation in the gene for Vascular Endothelial Growth Factor is associated with Vascular Endothelial Growth Factor plasma level. *J Vasc Res*;37:443-448.

Rodrigues, P., Furriol, J., Tormo, E., Ballester, S., Lluch A., Eroles, P., 2012. The single-nucleotide polymorphisms+ 936 C/T VEGF and-710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population, *Breast Cancer Res Treat*; 133(2):769–778.

rs3025039 (SNP) - Population genetics - Homo sapiens - Ensembl genome browser 92 [Internet]. [cited 2018 Jul 10]. Available from: http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=6:43784299-43785299;v=rs3025039;vdb=variation;vf=2313204

Russel, J.W., Zilliox, L.A., 2014. Diabetic Neuropathies, *Continuum*;20(5):1226-1240.

Savabkar, S., Chalesi, V., Farahbakhsh,F.B., Haghighi, M.M., Zali, N., Mojarad, E.N., Vahedi, M., Javadi, G.R., Aghdaei, H.A., Zali, M.R., 2015. VEGF gene+ 936C/T polymorphism decreases the risk of colorectal cancer, *Eur J Oncol*, 20(2):88–93.

Schreiber, A.K., Nones, C.F.M., Reis, R.C., Chichorro, J.G., Cunha, J.M., 2015. Diabetic neuropathic pain: Physiophysiology and treatment. *World J Diabetes*;6(3):432-444.

Shakeel, M., 2014. Recent advances in understanding the role of oxidative stress in diabetic neuropathy. *Diab Met Syndr: Clin Res Rev*;2014:1-6.

Shibuya, M., 2011. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis. A Crucial Target fot

Anti- and Pro-Angiogenic Therapies. *Genes Cancer*;2(12):1097-1105.

Shibuya, M., 2013. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases, *J Biochem*;153(1):13-19

Shimizu, F., Sano, Y., Haruki, H., Kanda, T., 2011. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by stimulating the release of TGF-à and vascular endothelial growth factor (VEGF) by pericytes. *Diabetologia*;54:1517-1526

Smith, A.G., Singleton J.R., 2013. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. *J Diabetes Complications*;27(5):436-442.

Soewondo, P., Ferrario, A. and Tahapary, D. L. 2013. Challenges in diabetes management in Indonesia: a literature review, *Global Health*; 9(1):63.

Soewondo, P., Soegondo, S., Suastika, K., Pranoto, A., Soeatmadji, D.W., Tjokroprawiro, A., 2010. The DiabCare Asia 2008 study-Outcomes on control and complications of type 2 diabetic patients in Indonesia, *Med J Indones*; 19(4):235-244

Sreenivasan, A., Mansukhani, K.A., Sharma, A. and Balakrishnan, L., 2016. Sural sensory nerve action potential: A study in healthy Indian subjects. *Ann Indian Acad Neurol;*19(3):312.

Susanna, M., Dachlan, E.G., 2015. Analysis of vascular endothelial growth factor (VEGF +405G>C and +936C>T gene polymorphisms in early onset severe preeclampsia. *Pregnancy Hypertens*;5(1):53

Tahergorabi, Z. and Khazaei, M. (2012) ‘Imbalance of angiogenesis in diabetic complications: the mechanisms’, *International journal of preventive medicine*, 3(12), p. 827.

Takahashi, H., Shibuya, M., 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological dan pathological conditions. *Clin Sci*;109:227-241.

Tarr, J.M., Kaul, K., Chopra, M., Kohner, E. M., and Chibner, R. 2012. Pathophysiology of Diabetic Retinopathy. *IRSN Ophtalmology*;2013

Tavakkoly-Bazzaz, J., Amoli, M.M., Pravica, V., Chandrasecaran, R., Boulton, A.J., Larijani, B., Hutchinson, I.V., 2010. VEGF gene polymorphism association with diabetic neuropathy. *Mol Biol Rep*;37(7):3625-3630.

Tesfaye, S., 2011. Recent advances in the management of diabetic distal symmetrical polyneuropathy. *J Diabetes Invest*;2(1):33-42

Tesfaye, S., Boulton, A.J.M., Dyck, P.J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R.A., Spallone, V., Bernardi, L., and Valensi, P., 2010. Diabetic neuropathies: update on definitions, diagnostic criteria, ertimation of severity, and treatments. *Diabetes Care*;33:2285-2293.

Tesfaye, S., Chaturvedi, N., Eaton, S.E.M., Ward, J.D., Manes, C., Ionescu-Tigorviste, C., et al., 2005. Vascular Risk Factors and Diabetic Neuropathy. *NEJM*;352:341-350.

Tesfaye, S., Selvarajah, D., 2012. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. *Diabetes Metab Res Rev*;28(Suppl 1):8-14.

Valensi P., Picard, S. Lipids, lipid lowering therapy and diabetes complications. *Diabetes & Metabolism*;37:15-24.

Van Acker, K., Bouhassira, D., De Bacquer, D., Weiss, S., Matthys, K., Raemen, H., Mathieu, C., Colin, I.M., 2009. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetes patients attending hospital outpatients clinics. *Diabetes Metab*;35(3):206-213.

Verheyen, A., Peeraer, E., Lambrechts, D., Poesen, K., Carmeliet, P., Shibuya, M., Pintelon, I., Timmermans, J.P., Nuydens, R., Meert, T.

Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. *Neuroscience*;244:77-89.

Veves, A., King, G. L., 2001. Can VEGF reverse diabetic neuropathy in human subjects? *J Clin Inves*;107:1215-1218.

Vincent, A.M., Russell, J.W., Low, P., Feldman, E.L., 2004. Oxidative stress in the pathogenesis of diabetic neuropathy. *Endocr Rev*;25(4):612-628.

Vincent, A.M., Hindler, L.M., Pop-Busui, R., Feldman, E.L., 2009. Hyperlipidemia: a new therapeutic target for Diabetic Neuropathy. *J Peripher Nerv Syst.*;14(4):257-276.

Vincent A. M. Callaghan, B.C., Smith, A.L., Feldman, E.L., 2011. Diabetic neuropathy: cellular mechanisms as therapeutic targets. *Nat Rev Neurol*;7:573-583.

Wang, A.K., and Rutkove, S.B. 2007. Electrophysiology of Polyneuropathy. In. Blum AS and Rutkove, SB, *The Clinical Neurophysiology Primer*. Humana Press, Totowa, New Jersey, pp 275-285

Weisman, A., Bril, V., Ngo, M., Lovblom, L.E., Halpem, E.M., Orszag, A., et al. Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combination of Nerve Conduction Study Parameters. *PLOS One*;8(3):e58783.

Weiss, L. 2004. Peripheral Neuropathy. In. Weiss, L., Silver, J.K., Weiss, J. Eds. Easy EMG: A Guide to Performing Nerve Conduction Studies and Electromyography. Elsevier, pp. 161-166.

Widjaja, D., 2008. Pemeriksaan Neurofisiologik pada Sindroma Nyeri Akut dan Menahun. In. Meliala, L., Suryamiharja, A., Wirawan, R.B., Sadeli, H.A., Amir, D., Eds. Nyeri Neuropatik. Medikagama Press, Yogyakarta, pp.30-49.

Wild, S., Roglic, G., Sicree, R., Green, A., King, H., 2000. Global burden of diabetes mellitus in the year 2000. World Health Organization.

Won, J.C., Kim, S.S., Ko, K.S., Cha, B.Y., 2014. Current Status of Diabetic Peripheral Neuropathy in Korea: Report of a Hospital-Based Study

of Type 2 Diabetic Patiens in Korea by the Diabetic Neuropathy Study Group of the Korean Diabetes Association. *Diabetes Metab J*;38:25-31.

Yagihashi, S., Yamagishi, S.I., Wadam R., 2007. Pathology and pathogenic mechanism of diabetic neuropathy: Correlation with clinical sign and symptoms. *Diabetes Res Clin Pract*; 77S:S184-S189.

Yang, C.P, Lin, C.C., Li, C.I., Liu, C.S., Lin, W.Y., Hwang, K.L., Yang, S.Y., Chen, H.J., Li, T.C., 2015. Cardiovascular risk factors increase the risks of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. *Medicine*;94(42):1-10.

Younes, T.B., Elattar, E.A., 2013. Electrophysiological assessment of hand elevation test in the diagnosis of carpal tunnel syndrome. *Egypt Rheumatol Rehabil*;40:203-210.

Zacchigna, S., Lambrechts, D., Carmeliet, P., 2008. Neurovascular signalling defects in neurodegeneration. *Nature Rev Neurosci*;9(3):169

Ziegler, D., Papanas, N., Vinik, A.I., Shaw, J.E., 2014. Epidemiology of polyneuropathy in diabetes and prediabetes. Handbook of clinical neurology; 126, pp. 3–22.

Zhang, X., Sun, Z., Jiang, H., Song, X., 2014. Relationship between single nucleotide polymorphisms in 3'-untranslated region of the vascular endothelial growth factor gene and susceptibility to diabetic peripheral neuropathy in China. *Arch Med Sci*;10(5): 1028-1034.

Zorina-Lichtenwalter, K., Parisien, M. and Diatchenko, L., 2018. Genetic studies of human neuropathic pain conditions: a review. *Pain*;159(3):583-594